It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Ferroptosis, which is characterized by intracellular iron accumulation and lipid peroxidation, is a newly described form of regulated cell death that may play a key role in tumour suppression. In the present study, we investigated the expression profiles and biological effects of fascin actin-bundling protein 1 (Fascin, gene name FSCN1) in breast cancer. In addition, bioinformatics analysis of the TCGA cancer database and gain- and loss-of-function studies showed that Fascin enhances sensitivity to erastin-induced ferroptosis. Mechanistically, Fascin directly interacts with cysteine/glutamate transporter (xCT, gene name SLC7A11) and decreases its stability via the ubiquitin-mediated proteasome degradation pathway. Furthermore, we observed that Fascin is substantially upregulated in tamoxifen-resistant breast cancer cell lines, and drug-resistant cells were also more vulnerable to erastin-induced ferroptosis. Taken together, our findings reveal a previously unidentified role of Fascin in ferroptosis by regulating xCT. Thus, ferroptosis activation in breast cancer with high Fascin level may serve as a potential treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Zhejiang University School of Medicine, Department of Surgical Oncology, Sir Run Run Shaw Hospital, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China (GRID:grid.13402.34)
2 Zhejiang University School of Medicine, Department of Surgical Oncology, Sir Run Run Shaw Hospital, Hangzhou, China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou, China (GRID:grid.13402.34); Wenzhou Medical University, Department of Surgical Oncology, Taizhou Hospital, Taizhou, China (GRID:grid.268099.c) (ISNI:0000 0001 0348 3990)